Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment (2022)
- Authors:
- USP affiliated authors: TOLEDO, MONICA FRANCO ZANNINI JUNQUEIRA - FCF ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; LOTUFO, LETICIA VERAS COSTA - ICB ; PARISE FILHO, ROBERTO - FCF ; WAITMAN, KAROLINE DE BARROS - FCF ; ALMEIDA, LARISSA COSTA DE - ICB
- Unidades: FCF; ICB
- Subjects: NEOPLASIAS; PURINAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher: Sociedade Brasileira de Química/SBQ
- Publisher place: São Paulo
- Date published: 2022
- Source:
- Título do periódico: Anais
- Conference titles: Reunião Anual da Sociedade Brasileira de Química
-
ABNT
WAITMAN, Karoline de Barros et al. Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment. 2022, Anais.. São Paulo: Sociedade Brasileira de Química/SBQ, 2022. Disponível em: http://www.sbq.org.br/45ra/anexos/45RASBQ_resumos.pdf. Acesso em: 30 abr. 2024. -
APA
Waitman, K. de B., Tavares, M. T., Almeida, L. C. de, Toledo, M. F. Z. J., Machado Neto, J. A., Lotufo, L. V. C., & Parise Filho, R. (2022). Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment. In Anais. São Paulo: Sociedade Brasileira de Química/SBQ. Recuperado de http://www.sbq.org.br/45ra/anexos/45RASBQ_resumos.pdf -
NLM
Waitman K de B, Tavares MT, Almeida LC de, Toledo MFZJ, Machado Neto JA, Lotufo LVC, Parise Filho R. Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment [Internet]. Anais. 2022 ;[citado 2024 abr. 30 ] Available from: http://www.sbq.org.br/45ra/anexos/45RASBQ_resumos.pdf -
Vancouver
Waitman K de B, Tavares MT, Almeida LC de, Toledo MFZJ, Machado Neto JA, Lotufo LVC, Parise Filho R. Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment [Internet]. Anais. 2022 ;[citado 2024 abr. 30 ] Available from: http://www.sbq.org.br/45ra/anexos/45RASBQ_resumos.pdf - Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment
- Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models
- HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents
- DNA damaging agents and DNA repair: from carcinogenesis to cancer therapy
- A novel HDAC inhibitor potentiates Venetoclax-induced apoptosis in acute myeloid leukemia cells
- Synthesis and biological evaluation of hybrid inhibitors for the treatment of hematologic malignancies
- Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors
- ANKHD1 contributes to the malignant phenotype of triple-negative breast cancer cells
- New kinase and HDAC hybrid inhibitors: recent advances and perspectives
- Novel [6]-gingerol triazole derivatives and their antiproliferative potential against tumor cells
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | 3090683.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
